Skip to main navigation
Investor Relations
Company StatementsMedia ContactEmail Alerts
Events & PresentationsFinancialsStock InformationGovernanceResources
PatientsTeamCommunityEnvironmentCompliance & Transparency
Our LocationsMedical Information
magnifying glass icon
Incyte Home
Main Nav
  • Our Company
  • What We Do
  • Culture & Careers
  • Patient Resources
  • HCP Resources
  • Our Stories
  • Responsibility
  • Our Company
    • Our Leadership
  • What We Do
    • Portfolio
    • Oncology
      • Approved Therapies
      • HCP Resources
    • Dermatology
      • Approved Therapies
      • HCP Resources
    • Partnerships
  • Culture & Careers
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • Responsibility
    • Patients
    • Team
    • Community
    • Environment
    • Compliance & Transparency
Main Nav
  • magnifying glass icon
  • Our Company
    • magnifying glass icon
    • Our Leadership
  • What We Do
    • magnifying glass icon
    • Portfolio
    • Oncology
    • Dermatology
    • Partnerships
  • Culture & Careers
    • magnifying glass icon
    • Open Positions
    • Incyte Involved
    • Inclusion
  • Patient Resources
  • HCP Resources
  • Our Stories
  • News
    • magnifying glass icon
    • Company Statements
    • Media Contact
    • Email Alerts
  • Investors
    • magnifying glass icon
    • Events & Presentations
    • Financials
    • Stock Information
    • Governance
    • Resources
  • Responsibility
    • magnifying glass icon
    • Patients
    • Team
    • Community
    • Environment
    • Compliance & Transparency
  • Contact Us
    • magnifying glass icon
    • Our Locations
    • Medical Information
  • United States
Home  >  Investors

Incyte International Locations

NORTH AMERICA— HEADQUARTERS

DENMARK

ITALY

SPAIN

UNITED KINGDOM

EUROPE— HEADQUARTERS

FINLAND

JAPAN

SWEDEN

AUSTRIA

FRANCE

THE NETHERLANDS

SWITZERLAND

CANADA

GERMANY

NORWAY

PORTUGAL

Close

Investors

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Quick Links

  • Investor Presentation
  • Responsibility
  • News
  • Portfolio
  • Responsibility Report
  • Annual Reports
  • Leadership
  • Governance
  • SEC Filings

Latest Press Releases

May 25, 2023
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
May 23, 2023
Incyte to Present at Upcoming Investor Conferences
May 8, 2023
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
All press releases

Latest Events

Jun 12 2023 Jun 12 2023
Goldman Sachs Annual Global Healthcare Conference
Click here for Webcast
Jun 6 2023 Jun 6 2023
William Blair Annual Growth Stock Conference
Click here for Webcast
All events
Market Cap:
Volume:
May 22, 2023 1:24 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Info
Show all

Q1 2023 RESULTS

  • Press Release
  • Presentation 4 MB
  • Webcast
  • Transcript 275.2 KB
All Quarterly Results

Investor Contacts

Greg Shertzer, PharmD

Associate Director, Investor Relations

302.274.4779

gshertzer@incyte.com

Incyte Home © 2012-2023 Incyte.
  • Facebook Icon
  • LinkedIn Icon
  • Twitter Icon
  • Youtube Icon
  • Legal Notice
  • Privacy Policy
  • Cookie Policy
  • Suppliers
  • Site Map